Ireland· IE-PA-EU/1/16/1116/001
Epclusa 400 mg/100 mg film-coated tablets
A direct acting antivirals product containing sofosbuvir + velpatasvir, registered in Ireland by Gilead Sciences Ireland UC.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Sofosbuvir + Velpatasvir
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Ireland (IE)
- ATC code
- J05A
- ATC class
- DIRECT ACTING ANTIVIRALS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/16/1116/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir + velpatasvir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEpclusaGilead Sciences, Inc.
- SpainEPCLUSA 150 MG/37,5 MG GRANULADO RECUBIERTO EN SOBREGilead Sciences Ireland Unlimited Company
- FinlandEpclusaGilead Sciences Ireland UC
- United KingdomEpclusa 150mg/37.5mg granules sachetsGilead Sciences Ltd
- SwedenEpclusa 150 mg/37,5 mg Dragerat granulat i dospåseGilead Sciences Ireland UC
- IcelandEpclusaGilead Sciences Ireland UC*
- NetherlandsEpclusa 150 mg/37,5 mg, omhuld granulaat in sachetGilead Sciences Ireland UC
- PolandEpclusaGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Epclusa
- Liechtenstein · Epclusa
- Norway · Epclusa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ec8d4e0b-30a4-4f21-8b2c-01c71ae64616 GET /v1/drugs/ec8d4e0b-30a4-4f21-8b2c-01c71ae64616?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"J05A"
],
"strength": null,
"pa_number": "EU/1/16/1116/001",
"substances": [
"Sofosbuvir",
"Velpatasvir"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about sofosbuvir + velpatasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.